IBDEI0LM ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10082,1,4,0)
 ;;=4^E10.349
 ;;^UTILITY(U,$J,358.3,10082,2)
 ;;=^5002599
 ;;^UTILITY(U,$J,358.3,10083,0)
 ;;=E10.351^^44^500^7
 ;;^UTILITY(U,$J,358.3,10083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10083,1,3,0)
 ;;=3^DM Type 1 w/ Prolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10083,1,4,0)
 ;;=4^E10.351
 ;;^UTILITY(U,$J,358.3,10083,2)
 ;;=^5002600
 ;;^UTILITY(U,$J,358.3,10084,0)
 ;;=E10.359^^44^500^8
 ;;^UTILITY(U,$J,358.3,10084,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10084,1,3,0)
 ;;=3^DM Type 1 w/ Prolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10084,1,4,0)
 ;;=4^E10.359
 ;;^UTILITY(U,$J,358.3,10084,2)
 ;;=^5002601
 ;;^UTILITY(U,$J,358.3,10085,0)
 ;;=E08.311^^44^500^39
 ;;^UTILITY(U,$J,358.3,10085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10085,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10085,1,4,0)
 ;;=4^E08.311
 ;;^UTILITY(U,$J,358.3,10085,2)
 ;;=^5002510
 ;;^UTILITY(U,$J,358.3,10086,0)
 ;;=E08.319^^44^500^40
 ;;^UTILITY(U,$J,358.3,10086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10086,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10086,1,4,0)
 ;;=4^E08.319
 ;;^UTILITY(U,$J,358.3,10086,2)
 ;;=^5002511
 ;;^UTILITY(U,$J,358.3,10087,0)
 ;;=E08.321^^44^500^41
 ;;^UTILITY(U,$J,358.3,10087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10087,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Mild Nonprolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10087,1,4,0)
 ;;=4^E08.321
 ;;^UTILITY(U,$J,358.3,10087,2)
 ;;=^5002512
 ;;^UTILITY(U,$J,358.3,10088,0)
 ;;=E08.329^^44^500^42
 ;;^UTILITY(U,$J,358.3,10088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10088,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Mild Nonprolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10088,1,4,0)
 ;;=4^E08.329
 ;;^UTILITY(U,$J,358.3,10088,2)
 ;;=^5002513
 ;;^UTILITY(U,$J,358.3,10089,0)
 ;;=E08.331^^44^500^43
 ;;^UTILITY(U,$J,358.3,10089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10089,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Moderate Nonprolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10089,1,4,0)
 ;;=4^E08.331
 ;;^UTILITY(U,$J,358.3,10089,2)
 ;;=^5002514
 ;;^UTILITY(U,$J,358.3,10090,0)
 ;;=E08.339^^44^500^44
 ;;^UTILITY(U,$J,358.3,10090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10090,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Moderate Nonprolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10090,1,4,0)
 ;;=4^E08.339
 ;;^UTILITY(U,$J,358.3,10090,2)
 ;;=^5002515
 ;;^UTILITY(U,$J,358.3,10091,0)
 ;;=E08.341^^44^500^47
 ;;^UTILITY(U,$J,358.3,10091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10091,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Severe Nonprolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10091,1,4,0)
 ;;=4^E08.341
 ;;^UTILITY(U,$J,358.3,10091,2)
 ;;=^5002516
 ;;^UTILITY(U,$J,358.3,10092,0)
 ;;=E08.349^^44^500^48
 ;;^UTILITY(U,$J,358.3,10092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10092,1,3,0)
 ;;=3^Diab d/t Undrl Cond w/ Severe Nonprolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10092,1,4,0)
 ;;=4^E08.349
 ;;^UTILITY(U,$J,358.3,10092,2)
 ;;=^5002517
 ;;^UTILITY(U,$J,358.3,10093,0)
 ;;=E09.311^^44^500^37
 ;;^UTILITY(U,$J,358.3,10093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10093,1,3,0)
 ;;=3^Diab d/t Drug/Chem w/ Unspec Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10093,1,4,0)
 ;;=4^E09.311
 ;;^UTILITY(U,$J,358.3,10093,2)
 ;;=^5002552
 ;;^UTILITY(U,$J,358.3,10094,0)
 ;;=E09.319^^44^500^38
